ML 7 hydrochloride
Cat. No. 4310
Chemical Name: Hexahydro-1-[(5-iodo-1-naphthalenyl
Biological ActivitySelective MLCK inhibitor (Ki = 0.3 μM). Exhibits more potent inhibition than ML 9 hydrochloride (Cat. No. 0431) Displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. Inhibits proplatelet formation and stabilization.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Meinders et al (2015) Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function. Blood 125 1957. PMID: 25538045.
Saitoh et al (1987) Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J.Biol.Chem. 262 7796. PMID: 3108259.
If you know of a relevant reference for ML 7 hydrochloride please let us know.
Citations are publications that use Tocris products. Selected citations for ML 7 hydrochloride include:
Chaudhuri et al (2015) Substrate stress relaxation regulates cell spreading. J Neurosci 6 6364. PMID: 25695512.
Leoni et al (2015) Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest 125 1215. PMID: 25664854.
Siddoway et al (2013) An essential role for inhibitor-2 regulation of protein phosphatase-1 in synaptic scaling. Am J Physiol Renal Physiol 33 11206. PMID: 23825423.
Do you know of a great paper that uses ML 7 hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: ML 7 hydrochloride, supplier, ML7, HCl, MLC, kinase, inhibitor, inhibits, myosin, light, chain, kinase, inhibitors, MLCKs, platelets, Tocris Bioscience, Myosin Light Chain Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitor
May 17 - 19, 2017